Get started
Author

Adam Kidwell

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
2024 · Meghan C. Thompson, Seema A. Bhat, et al. · Blood · 7
PDF
The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
2024 · Edward R Scheffer Cliff, Guido D Pelaez, et al. · Blood · 4
PDF
Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium
2025 · Max Kelsten, Colin Thomas, et al. · Blood · 3
PDF
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
2025 · Edward R. Scheffer Cliff, Guido D. Pelaez, et al. · Clinical Cancer Research · 3
Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL
2024 · Adam Kidwell, Fateeha Furqan, et al. · Blood · 1
PDF
Dosing Factor in Pediatric and Adult Hemophilia Patients Using Ideal Body Weight Versus actual Body Weight
2016 · Adam P Kidwell, Nidhi Bhatt, et al. · Blood · 1
Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas
2026 · Victoria Anne Gill, Thomas A. Ollila, et al. · Blood Advances
PDF
Real World Outcomes and Predictive Factors of Pirtobrutinib in Mantle Cell Lymphoma After Failure of Covalent Bruton Tyrosine Kinase Inhibitors
2026 · Tycel Phillips, Paolo Lopedote, et al. · Research Square
PDF
Disseminated Fusarium infection following cladribine chemotherapy for hairy-cell leukaemia
2026 · Matthew Dandan, Saba Anwer, et al. · BMJ Case Reports
Adjuvant trastuzumab with or without pertuzumab after pathologic complete response to neoadjuvant HER2-targeted therapy and chemotherapy in HER2-positive breast cancer: A retrospective cohort study.
2026 · James Fradin, Amber Haugen, et al. · Journal of Clinical Oncology
Intrathecal Therapy for Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): An Updated Multicenter Analysis of Outcomes and Safety
2026 · Adam Kidwell, Karolina Lungova, et al. · Transplantation and Cellular Therapy
Rethinking Surveillance: Low Incidence of Late-Onset Toxicities across CD-19 CAR T-cell Constructs Supports Reduced Monitoring
2026 · Megan Melody, Adit Dharia, et al. · Transplantation and Cellular Therapy
Data from Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
2026 · Edward R. Scheffer Cliff, Guido D. Pelaez, et al.
Supplemental Table 1 from Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
2026 · Edward R. Scheffer Cliff, Guido D. Pelaez, et al.
Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes
2025 · Adam Kidwell, Karolina Lungova, et al. · Blood
Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians
2025 · Lindsey Fitzgerald, Elena Nazarenko, et al. · Blood
PDF
Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium
2025 · Victoria Gill, Ari Pelcovits, et al. · Blood
PDF
Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies
2025 · Daniel Reef, Nicole Altomare, et al. · Blood
PDF
Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy
2025 · Timothy Oh, Ari Pelcovits, et al. · Blood
Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL
2025 · Megan Melody, Alan Kerr, et al. · Blood
LV20.19 CAR T cells for methotrexate relapsed/refractory primary or secondary CNS lymphoma with parenchymal involvement
2025 · Ashley Dunton, Adam Kidwell, et al. · Blood
PDF
Improved Predication of Response and Relapse in Nodal B-Cell Lymphomas with the Use of Ctdna As Compared to Cellular Assays for Measurable Residual Disease
2025 · Adam Kidwell, Tyce Kearl, et al. · Transplantation and Cellular Therapy
Bilateral Lower Extremity Pain and Weakness in a 15-year-old Boy
2023 · Adam Kidwell, Teresa Kelly, et al. · Pediatrics in Review
Measles immune status in an inner city pediatric oncology patient cohort during the measles outbreak of 2015.
2016 · Nupur Mittal, Paul Kent, et al. · Journal of Clinical Oncology
Works count: 24
Citation count: 18
H-index: 3
I10-index:
Year
Topic
Type